Home

Dr. Benjamin E Blass

Selected Publications and Presentations:

  1. Development of a novel non-radiometric assay for nucleic acid binding to TDP-43 suitable for high-throughput screening using AlphaScreenÃ’ technology, Cassel, J. A.; Blass, B. E.; Reitz, A. B.; Pawlyk, A. C. J. Biomol. Screen. 2010, in press.
  2. Development of a novel non-radiometric assay for nucleic acid binding to TDP-43 suitable for high-throughput screening using AlphaScreen technology. Pawlyk A.C.; Cassel J.A.; Blass B.E.; Reitz A.B., Society for Neuroscience, San Diego, CA, 2010.
  3. Selective Kv1.5 blockers: Development of KVI-020/WYE-160020 as a potential treatment for atrial arrhythmia, Blass, B. E.; Fensome, A.; Trybulski, E.; Magolda, R.; Gardell, S.; Liu, K.; Samuel, M.; Feingold, I.; Huselton, C.; Jackson, C.; Djandjighian, L.; Ho, D.; Hennan, J.; Janusz, J. J. Med. Chem. 2009, 52, 21, 6531-6534.
  4. Selective Kv1.5 blockers: Development of KVI-020 as a potential treatment for atrial arrhythmia, Blass, B. E.;  Coghlan, R.; Fensome, A.; Steffan, R.; Trybulski, E.; Vera, M.; Vu, A.; Webb, M.; Cross, J; Unwalla,R.; Hennan, J.; Liu, K.; Samuel, M.; Eta, J.; Feingold, I.; Huselton, C.; Kao, J.; Tio, C.; Vlasuk, G.; Morgan, G.; Swillo, R.; Rossman, E. I.; Janusz, J. M.; Jackson, C. M.; Djandjighian, L.; Hedges, R. 238th American Chemical Society National Meeting, Aug. 16-20, 2009.
  5. Kv1.5 inhibitor, WYE-160020, reduces atrial fibrillation/flutter inducibility in post-operative sterile pericarditis and simultaneous atrial/ventricular tachypacing canine models, Rossman, E.I.; Morgan, G.A.; Swillo, R.E.; Liu, K.; Blass, B. E.; Jackson, C. M.; Janusz, J. M.; Fensome, A.; Trybulski, E. J.; Gardell, S. J.; Vlasuk, G. P.; Hennan, J.K., 30th Annual Heart Rhythm Society Meeting, Boston, MA, May 13-16th, 2009.
  6. 1,4-Dihydro-1-(phenylmethyl)-3-pyridinecarboxamide, Blass, B.E. Encyclopedia of Reagents for Organic Synthesis, 2008.
  7. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias, Jackson, C. M.; Blass, B.; Coburn, K.; Djandjighian, L.; Fadayel, G.; Fluxe, A. J.; Hodson, S. J.; Janusz, J. M.; Murawsky, M.; Ridgeway, J. M.; White, R. E.; Wu, S. Biorg. Med. Chem. Lett. 2007, 17, 1, 282-284.
  8. Synthesis of 1-aminoimidazolidin-4-one and 1-aminoimidazolidin-2-one based compounds: An interesting divergence in methodology, Blass, B. E.; Coburn, K.; Fairweather, N.; Fluxe, A.; Hodson, S.; Jackson, C.; Janusz, J.; Lee, W.; Ridgeway, J.; White, R.; Wu, S. Tetrahedron Lett. 2006, 47, 42, 7497-7499.
  9. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation, Blass, B. E.; Coburn, K.; Lee, W.; Fairweather, N.; Fluxe, A.; Wu, S.; Janusz, J. M.; Murawsky, M.; Fadayel, G.; Fang, B.; Hare, M.; Ridgeway, J.; White, R.; Jackson, C.; Djandjighian, L.;  Hedges, R.;  Wireko, F. C.; Ritter, A. Biorg. Med. Chem. Lett. 2006, 16, 17, 4629-4632.
  10. Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 inhibitors, Wu, S.; Blass, B. E.; Coburn, K.; Lee, W.; Fairweather, N.; Fluxe, A.; Janusz, J. M.; Murawsky, M.; Fadayel, G.; Fang, B.; Hare, M.; Ridgeway, J.; White, R.; Jackson, C.; Djandjighian, L.;  Hedges, R.;  Wireko, F. C.; Ritter, A. Biorg. Med. Chem. Lett. 2006, 16, 24, 6213-6218.
  11. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers, Wu, S.; Blass, B. E.; Coburn, K.; Lee, W.; Fairweather, N.; Fluxe, A.; Janusz, J. M.; Murawsky, M.; Fadayel, G.; Fang, B.; Hare, M.; Ridgeway, J.; White, R.; Jackson, C.; Djandjighian, L.;  Hedges, R.;  Wireko, F. C.; Ritter, A. Biorg. Med. Chem. Lett. 2006, 16, 22, 5859-5863.
  12. A facile, KF/Al2O3 mediated method for the preparation of functionalized pyrido[2,3-d]pyrimidin-7(8H)-ones, Blass, B. E.; Coburn, K. R.;Fairweather, N.; Sabat, M.; West, L., Tetrahedron Lett. 2006, 47, 18, 3177-3180.
  13. Solid-phase approach towards the synthesis of functionalized imidazo [1,2-b] pyrazol-2-ones, Blass, B. E.; Srivastava, A.; Coburn, K. R.; Faulkner, A. L.; Janusz, J. J.; Ridgeway, J. M.; Seibel, W. L. Tetrahedron Lett. 2004, 45, 6, 1275-77.
  14. Solution phase synthesis of imidazo [1,2-b] pyrazol-2-one, an interesting 5,5-fused heterocyclic ring system, Blass, B. E.; Srivastava, A.; Coburn, K. R.; Faulkner, A. L.; Janusz, J. J.; Ridgeway, J. M.; Seibel, W. L. Tetrahedron Lett. 2004, 45, 3, 619-621.
  15. A simple method for the preparation and selective functionalization of4,5-diaminopyrazoles, Blass, B.E.; Coburn, K. R.; Faulkner, A. L.; Seibel,W. L.; Srivastava, A. Tetrahedron Lett. 2003, 44, 14, 3009-3011.
  16. Applications of solid supported azide anion: A one-pot, two-step preparation of functionalized 1,2,3-triazoles, Blass, B.E.; Coburn, K. R.: Faulkner, A. L.; Seibel, W. L.; Srivastava, A. Tetrahedron Lett. 2003, 44, 10, 2153-2155.
  17. KF/Al2O3 mediated organic synthesis, Blass, B.E. Tetrahedron, 2002 58, 46, 9301-9320.
  18. Solid phase synthesis of funtionalized 1,2,4-triazin-6-ones, Blass, B. E.; Coburn, K. R., Faulkner, A. L.; Liu, S.; Ogden, A.; Portlock, D .E.; Srivastava, A.; Tetrahedron Lett. 2002, 43, 45, 8165-8167.
  19. Solid phase synthesis of funtionalized 1,2,3-triazoles, Blass, B. E.; Coburn, K. R., Faulkner, A. L.; Hunn, C. L.; Natchus, M. G.; Parker, M.S.;  Portlock, D .E.; Tullis, J. S.; Wood, R. Tetrahedron Lett. 2002, 43, 4059-4061.
  20. A facile, selective KF/ Al2O3 mediated method for the deprotection of aryl silyl ethers and preparation of aryl SEM ethers, Blass, B. E.; Harris, C. L.; Portlock, D. E. Tetrahedron Lett. 2001, 42, 1611-1613.

Selected Patents and Patent Applications:

  1. Kv1.5 potassium channel inhibitors, Janusz, J. M.; Hodson, S. J.; Bosch G. K.; White R. E.; Blass B. E.; Jackson C. M.; Fairweather, N. T. US Patent 7803827, 2010.
  2. Preparation of 4-imidazolidinones as Kv1.5 potassium channel inhibitors, Blass, B. E.; Janusz, J. M.; Wu, S.; Ridgeway, J. M.; Coburn, K.; Lee, W.; Fluxe, A. J.; White, R. E.; Jackson, C. M.; Fairweather, N. WO 2009079624, 2009.
  3. Preparation of 4-imidazolidinones as Kv1.5 potassium channel inhibitors, Blass, B. E.; Janusz, J. M.; Ridgeway, J. M.; Wu, S. WO 2009079630, 2009.
  4. Kv1.5 potassium channel inhibitors, Janusz, J. M.; Hodson, S. J.; Bosch G. K.; White R. E.; Blass B. E.; Jackson C. M.; Fairweather, N. T. US Patent 7504517, 2009.
  5. Preparation of 4-oxo-1,3,8-triaza-spiro[4.5]decanes as Kv1.5 potassium channel inhibitors, Janusz, J. M.; Wu, S.; Fairweather, N. T.; Lee, W.; Blass, B. E.; Fluxe, A. J.; Hodson, S. J.; Ridgeway, J. M. WO  2007149873, 2007.
  6. Imidazolidinone derivatives as Kv1.5 potassium channel inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cardiac arrhythmia, Janusz, J. M.; Hodson, S. J.; Bosch, G. K.; White, R. E.; Blass, B. E.; Jackson, C. M.; Fairweather, N. T. WO 2007149874, 2007.
  7. Triazole compounds useful in treating diseases associated with unwanted cytokine activity, Tullis, J S.; Van Rens, J. C.; Clark, M. P.; Blass, B. E.; Natchus, M. G.; De, B. US Patent 6787555, 2004.
  8. Triazole compounds useful in treating diseases associated with unwanted cytokine activity, Tullis, J S.; Van Rens, J. C.; Clark, M. P.; Blass, B. E.; Natchus, M. G.; De, B. US Patent 6727364, 2004.
  9. Process for making functionalized oxazolidinone compounds, Blass, B. E. US Patent 6635769, 2003.
  10. N-(1-Phenylethyl)-5-phenyl-imidazole-2-amine compounds, their composition and uses, Blass, B. E.; Liu, S.; Portlock, D. E. US Patent 6596739, 2003.

Invited Lectures:

  1. Patent Law in the Pharmaceutical Industry, Temple University School of Pharmacy, April 2011.
  2. Drug Discovery and Development: Modern Methods and Principles, Delaware Valley College, March 2011.
  3. Modern Methods and Principles of Drug Discovery and Development, Temple University, Department of Biology, March 2011.
  4. Drug Discovery and Development: Modern Methods and Principles, University of Rochester, March 2011.
  5. Patent Law in the Pharmaceutical Industry, Drexel College of Medicine, November, 2010.
  6. Patent Law in the Pharmaceutical Industry, Drexel College of Medicine, 2010.
  7. Voltage-gated potassium channels as therapeutic targets, Pennsylvania Biotechnology Center, 2010.
  8. Combinatorial chemistry and the practical chemist’s tool box, Villanova University guest lecturer, 2008.

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140